Protocol Ledger

NCT05358548 · Phase II · RECRUITING

ATATcH Alternating Treatment Plans for Advanced Cancer

Interventional Phase II clinical trial protocol NCT05358548 sponsored by Rutgers, The State University of New Jersey in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-28 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05358548
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05358548
Protocol FieldVerified Registry Value
NCT IdentifierNCT05358548
Consolidated Lead SponsorRutgers, The State University of New Jersey
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2022-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05358548
Hospital Research SiteLocationSite Profile
Rutgers Cancer Institute of New JerseyNew Brunswick, NJOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI